New Jersey Tax Credits for Amneal Expansion
The pharmaceutical manufacturer receives $60.56 million in state incentives to fund a $240 million facility expansion.
Updated on Oct. 31, 2026 in Healthcare
Live Poll
Do you support state tax credits for private pharmaceutical companies to encourage local business expansion?
The New Jersey Economic Development Authority Board has approved $60.56 million in tax credits for Amneal Pharmaceuticals. This state funding supports a $240 million expansion of the company's manufacturing footprint to enhance domestic drug supply chain reliability.
Why it matters
The investment aims to bolster domestic capacity for complex medicine production by incentivizing the development of integrated manufacturing hubs. For regional operators, it reflects state-level efforts to reduce reliance on international pharmaceutical supply chains.
The project includes $60.56 million in tax credits awarded over five years to support a $240 million capital investment. The expansion is expected to create 330 new full-time positions as the company integrates eight buildings into a single manufacturing campus.
The players
New Jersey Economic Development Authority Board
A state agency that provides financial incentives and resources to support business growth and infrastructure development across New Jersey.
Amneal Pharmaceuticals
A specialty pharmaceutical manufacturer based in Bridgewater Township that produces over 300 types of medicine and supplies 160 million prescriptions annually.
The details
Amneal Pharmaceuticals will renovate eight buildings in Piscataway to create an integrated manufacturing campus focused on complex medicine development. The tax credits, issued through the Next New Jersey Manufacturing Program, are designed to offset the cost of the $240 million multi-year infrastructure investment. By consolidating manufacturing operations, the company aims to improve domestic supply reliability for its portfolio of over 300 generic and biosimilar products.
Timeline
2002: Amneal Pharmaceuticals was founded in Paterson.
Over three years: Amneal plans to execute the $240 million expansion.
Over five years: The state tax credit award is disbursed.
Market Landscape
This project follows the criteria established by the Next New Jersey Manufacturing Program to incentivize high-impact industrial infrastructure. The initiative signals a broader state trend of leveraging tax policy to secure domestic pharmaceutical supply chains.
Operators in the industrial and life sciences sectors should monitor state-led capital incentive programs for opportunities to subsidize long-term facility expansions. Businesses planning large-scale infrastructure projects should evaluate whether their site developments qualify for state manufacturing credit thresholds.
The takeaway
Large-scale manufacturing upgrades often hinge on state-backed incentives that trade capital investment for multi-year tax credits. Operators should maintain a list of active state incentive programs and cross-reference them against their three-to-five-year facility development pipelines.
Further reading
For broader trends in industry investment, read more in New Jersey Healthcare.
Source note: This article includes information reported by WRNJ Radio.
Live Poll
Do you support state tax credits for private pharmaceutical companies to encourage local business expansion?
